Did Bristol Myers Squibb beat expectations and raise guidance in Q2 2024?

The company raised its 2024 non-GAAP diluted EPS guidance to $0.60–$0.90 from $0.40–$0.70 and moved revenue guidance to the upper end of its low single-digit growth range. Q2 non-GAAP EPS of $2.07 was well above the prior-year $1.75, though part of the strength came from a $502M tax reserve release.

Why did GAAP EPS decline even though revenue grew?

GAAP EPS fell to $0.83 from $0.99 because of large non-recurring charges, including a $590M IPRD impairment tied to discontinuing alnuctamab, a $280M intangible asset impairment, higher amortization of acquired intangibles from recent acquisitions, and higher interest expense on new debt used to fund acquisitions.

How much of the quarter's earnings came from one-time tax benefits?

A $502M income tax reserve release is excluded from non-GAAP results only in part; it lowered the non-GAAP effective tax rate to 14.1% from 16.9%. The GAAP tax line was a $398M benefit on $1.3B of pre-tax earnings, so the release meaningfully inflated reported profitability in the quarter.

What is the outlook for key growth drivers and upcoming catalysts?

Growth drivers include Opdivo, Reblozyl, Camzyos, Opdualag and Breyanzi. Near-term catalysts include the KarXT FDA decision on September 26, 2024, the subcutaneous nivolumab PDUFA date of December 29, 2024, and Phase 3 data for cendakimab in eosinophilic esophagitis, which met both co-primary endpoints. Legacy Revlimid erosion from generics remains a headwind.

How is the company's balance sheet positioned after recent acquisitions?

Net debt rose to about $45.4B at June 30, 2024, from $27.1B at year-end 2023, and total debt was roughly $52.4B against about $7.0B of cash and marketable securities. Management has committed to paying down about $10B of debt over two years, reduced debt by about $3.1B in Q2, and said it remains committed to the dividend and has about $5B left under its share repurchase authorization.

BMY 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed July 26, 2024. Cited figures are marked; the original filing is the authoritative source.

Bristol Myers Squibb reported second-quarter 2024 results on July 26, 2024, with total revenues of $12.2 billion^a, up 9% reported (+11% excluding foreign exchange).

The growth was led by the Growth Portfolio, which reached $5.6 billion^b, up 18% reported (+21% ex-FX), driven by Opdivo, Reblozyl, Camzyos and Opdualag, partially offset by Abecma. Legacy Portfolio revenues were $6.6 billion, up 2%, with Eliquis and Pomalyst growth offset by Revlimid generic erosion. U.S. revenues rose 13% to $8.8 billion, while International revenues fell 1% to $3.4 billion, reflecting a 7-point foreign exchange headwind.

Profitability was mixed. GAAP EPS fell to $0.83^c from $0.99, weighed by a $280 million intangible asset impairment, a $590 million IPRD impairment tied to discontinuing alnuctamab, higher interest expense from debt raised for acquisitions, and restructuring costs. Non-GAAP EPS rose to $2.07 from $1.75, aided by a $502 million income tax reserve release that lowered the non-GAAP effective tax rate to 14.1%.

Investors should note that the GAAP tax benefit was $398 million^d on pre-tax earnings of $1.3 billion, so the reserve release materially flattered the quarter. Net debt rose to roughly $45.4 billion from $27.1 billion at year-end 2023. Management raised its 2024 non-GAAP guidance, with total revenue now expected at the upper end of the low single-digit growth range and diluted EPS raised to $0.60–$0.90 from $0.40–$0.70.

Pipeline news included positive Phase 3 cendakimab data in eosinophilic esophagitis, FDA approvals for Breyanzi in follicular and mantle cell lymphoma, and a subcutaneous nivolumab BLA with a PDUFA date of December 29, 2024. The Phase 3 CheckMate-73L trial in stage III NSCLC missed its primary endpoint, and KarXT's FDA decision is set for September 26, 2024.

02—Key points

Key Highlights

Q2 2024 total revenues of $12.2B, up 9% reported and 11% ex-FX; U.S. revenues up 13% to $8.8B while International fell 1% to $3.4B.
Growth Portfolio revenues rose 18% to $5.6B (21% ex-FX), led by Opdivo ($2.4B, +11%), Reblozyl (+82%), Camzyos and Breyanzi.
GAAP EPS of $0.83 (down from $0.99) included a $590M IPRD impairment, a $280M intangible asset impairment and higher interest expense; non-GAAP EPS rose to $2.07 from $1.75.
A $502M income tax reserve release drove the non-GAAP effective tax rate down to 14.1%, so the non-GAAP EPS beat is partly a tax benefit rather than purely operational.
2024 non-GAAP guidance raised: diluted EPS to $0.60–$0.90 (from $0.40–$0.70), revenue at the upper end of low single-digit growth, and gross margin to ~74–75%.
Net debt increased to about $45.4B from $27.1B at year-end 2023, following acquisitions; management plans roughly $10B of debt paydown over two years.
Regulatory and pipeline events: Breyanzi approved in follicular and mantle cell lymphoma, KarXT PDUFA date September 26, 2024, subcutaneous nivolumab PDUFA December 29, 2024, and the CheckMate-73L Phase 3 NSCLC trial missed its primary endpoint.

03—Questions

Frequently Asked Questions

Did Bristol Myers Squibb beat expectations and raise guidance in Q2 2024?
The company raised its 2024 non-GAAP diluted EPS guidance to $0.60–$0.90 from $0.40–$0.70 and moved revenue guidance to the upper end of its low single-digit growth range. Q2 non-GAAP EPS of $2.07 was well above the prior-year $1.75, though part of the strength came from a $502M tax reserve release.
Why did GAAP EPS decline even though revenue grew?
GAAP EPS fell to $0.83 from $0.99 because of large non-recurring charges, including a $590M IPRD impairment tied to discontinuing alnuctamab, a $280M intangible asset impairment, higher amortization of acquired intangibles from recent acquisitions, and higher interest expense on new debt used to fund acquisitions.
How much of the quarter's earnings came from one-time tax benefits?
A $502M income tax reserve release is excluded from non-GAAP results only in part; it lowered the non-GAAP effective tax rate to 14.1% from 16.9%. The GAAP tax line was a $398M benefit on $1.3B of pre-tax earnings, so the release meaningfully inflated reported profitability in the quarter.
What is the outlook for key growth drivers and upcoming catalysts?
Growth drivers include Opdivo, Reblozyl, Camzyos, Opdualag and Breyanzi. Near-term catalysts include the KarXT FDA decision on September 26, 2024, the subcutaneous nivolumab PDUFA date of December 29, 2024, and Phase 3 data for cendakimab in eosinophilic esophagitis, which met both co-primary endpoints. Legacy Revlimid erosion from generics remains a headwind.
How is the company's balance sheet positioned after recent acquisitions?
Net debt rose to about $45.4B at June 30, 2024, from $27.1B at year-end 2023, and total debt was roughly $52.4B against about $7.0B of cash and marketable securities. Management has committed to paying down about $10B of debt over two years, reduced debt by about $3.1B in Q2, and said it remains committed to the dividend and has about $5B left under its share repurchase authorization.

04—Continue

← View all 8-K filings